Is beta-trace protein an alternative marker of glomerular filtration rate in liver transplant recipients?

2011 ◽  
Vol 31 (9) ◽  
pp. 1345-1351 ◽  
Author(s):  
Thomas Gerhardt ◽  
Uwe Pöge ◽  
Birgit Stoffel-Wagner ◽  
Holger Palmedo ◽  
Tilman Sauerbruch ◽  
...  
2012 ◽  
Vol 142 (5) ◽  
pp. S-1000
Author(s):  
Alina M. Allen ◽  
Andrew D. Rule ◽  
Nelson Leung ◽  
Chun Fan ◽  
Terry M. Therneau ◽  
...  

Author(s):  
V. E. Syutkin ◽  
A. A. Salienko ◽  
O. D. Olisov ◽  
S. V. Zhuravel ◽  
M. S. Novruzbekov

Introduction. The lifelong use of calcineurin inhibitors in liver transplant recipients leads to an increased incidence of chronic kidney disease.Objective. To compare the changes in glomerular filtration rate over five years in liver transplant recipients between those on everolimus with a reduced exposure to calcineurin inhibitors and those on standard doses of calcineurin inhibitors.Material and methods. Fourteen liver transplant recipient switched to everolimus with a minimization of calcineurin inhibitors exposure in the first months after liver transplantation from February 2009 to February 2015 who had received that therapy continuously for at least 60 months were included in the case-control study. Twenty eight liver transplant recipients (matched by sex, etiology of the underlying disease, calcineurin inhibitors) who were followed-up for at least 60 months after liver transplantation, who had received no dose of everolimus, in whom the glomerular filtration rate could be calculated at all points of analysis were selected as a comparison group (1:2). Glomerular filtration rate was calculated immediately before liver transplantation; 12, 24, 36, 48, and 60 months after liver transplantation. The glomerular filtration rate after liver transplantation was also calculated for liver transplant recipients from the main group immediately before the conversion to everolimus.Results. Before liver transplantation, the median of glomerular filtration rate in the main group of liver transplant recipients was lower (81.2 ml/min) than in the comparison group (97.5 ml/min, p=0.01). After liver transplantation, the renal function worsened in both groups of patients. In a pairwise comparison, the medians of glomerular filtration rate were statistically significantly lower after 12 months, 24 months, 36 months, 48 months after liver transplantation, than before liver transplantation. The median of glomerular filtration rate at the time of immunosuppression conversion was 44.3 ml/min. After the conversion of immunosuppression, the median of glomerular filtration rate gradually increased, and after 36 months the differences in glomerular filtration rate reached statistical significance compared with the level before conversion (69.4 ml/min;p=0.048). These differences still increased after 60 months after conversion (72.3 ml/min; p=0.041).Conclusion. Long-term administration of everolimus with minimization of calcineurin inhibitors exposure with the early conversion to this immunosuppression regime provides a steady improvement in renal function in liver transplant recipients with a low glomerular filtration rate in the preoperative and early post-transplant period.


2021 ◽  
Author(s):  
Yasaman Saee ◽  
Simin Dashti-Khavidaki ◽  
Zahra Ahmadinejad ◽  
Fereshteh Ghiasvand

Abstract Background: In the setting of impaired liver function, estimation of glomerular filtration rate (GFR) using common creatinine based equations is inaccurate. Recently, Glomerular Filtration Rate Assessment in Liver Disease (GRAIL) model has been introduced for estimating GFR in liver transplantation. This study was conducted to compare vancomycin dose adjustment in liver transplant patients using Cockcroft-Gault (C-G) versus GRAIL method.Methods: In this pilot, randomized clinical trial, adult liver transplant recipients who were candidate to receive intravenous vancomycin were enrolled. GFR and creatinine clearance were estimated using GRAIL model and C-G equation in the intervention and control arms, respectively and vancomycin maintenance doses were adjusted accordingly. At the steady state , peak and trough serum concentrations of vancomycin were collected for pharmacokinetic comparisons.Results: Fifteen patients were enrolled in each arm of the study. Mean daily dose of vancomycin was estimated insignificantly lower for individuals in GRAIL arm than C-G group (1500.00±544.45 versus 1750.00± 389.60mg). The rate of patients who achieved the target vancomycin trough concentration was similar between the two study arms (20%). Compared with C-G group, higher rate of patients in GRAIL arm experienced below-target vancomycin trough concentrations (40% versus 13.3%) and lower rate showed above target trough concentration (40% versus 66.7%), although these differences did not reach statistical significance. Higher rates of patients with at target and above target vancomycin AUC/MIC were seen in the C-G group compared with GRAIL group (40% versus 26.7% and 53.3% versus 26.7%, respectively), while individuals in the GRAIL arm represented significantly higher rate of below target vancomycin AUC/MIC than C-G arm (46.7% versus 6.7%) (P=0.049). No differences in clinical outcomes were observed between the two groups.Conclusion: Using GRAIL model for vancomycin dose selection may result in less percent of patients with at target AUC/MIC exposure compared to C-G method and expose more percent of patients at risk of vancomycin under dosing.


2015 ◽  
Vol 61 (10) ◽  
pp. 1265-1272 ◽  
Author(s):  
Jeffrey W Meeusen ◽  
Andrew D Rule ◽  
Nikolay Voskoboev ◽  
Nikola A Baumann ◽  
John C Lieske

Abstract BACKGROUND The Kidney Disease Improving Global Outcomes (KDIGO) guideline recommends use of a cystatin C–based estimated glomerular filtration rate (eGFR) to confirm creatinine-based eGFR between 45 and 59 mL · min−1 · (1.73 m2)−1. Prior studies have demonstrated that comorbidities such as solid-organ transplant strongly influence the relationship between measured GFR, creatinine, and cystatin C. Our objective was to evaluate the performance of cystatin C–based eGFR equations compared with creatinine-based eGFR and measured GFR across different clinical presentations. METHODS We compared the performance of the CKD-EPI 2009 creatinine-based estimated GFR equation (eGFRCr) and the newer CKD-EPI 2012 cystatin C–based equations (eGFRCys and eGFRCr-Cys) with measured GFR (iothalamate renal clearance) across defined patient populations. Patients (n = 1652) were categorized as transplant recipients (n = 568 kidney; n = 319 other organ), known chronic kidney disease (CKD) patients (n = 618), or potential kidney donors (n = 147). RESULTS eGFRCr-Cys showed the most consistent performance across different clinical populations. Among potential kidney donors without CKD [stage 2 or higher; eGFR >60 mL · min−1 · (1.73 m2)−1], eGFRCys and eGFRCr-Cys demonstrated significantly less bias than eGFRCr; however, all 3 equations substantially underestimated GFR when eGFR was <60 mL · min−1 · (1.73 m2)−1. Among transplant recipients with CKD stage 3B or greater [eGFR <45 mL · min−1 · (1.73 m2)−1], eGFRCys was significantly more biased than eGFRCr. No clear differences in eGFR bias between equations were observed among known CKD patients regardless of eGFR range or in any patient group with a GFR between 45 and 59 mL · min−1 · (1.73 m2)−1. CONCLUSIONS The performance of eGFR equations depends on patient characteristics that are readily apparent on presentation. Among the 3 CKD-EPI equations, eGFRCr-Cys performed most consistently across the studied patient populations.


Sign in / Sign up

Export Citation Format

Share Document